KONINKLIJKE PHILIPS NV

A scaled, brand-strong healthcare-technology franchise whose current returns and growth are mid-pack, leaving it a solid but unremarkable C.

Strengths

• Strong liquidity/scale: cash & investments in the 93rd percentile, interest coverage ~4.9x (72nd pct) and ROA 3.3% (71st pct)
• Above-median operating margin (8.0%, 66th pct) and gross margin (45%, 56th pct) backed by a durable diagnostic-imaging brand, scale and IP
• Healthy interest coverage supports a moderate leverage profile despite debt/equity at the 70th percentile

Risks

• No standout metric: ROE only 8.2% (55th pct) and ROIC 5.9% — returns cluster near the sector median, not franchise-quality
• Negative momentum — revenue -1% (29th pct) and net income -2.3% (6.6th pct, near sector bottom)
• Overhang from Respironics recall/litigation and ongoing restructuring caps the upside and tempers the moat narrative

Notable findings

• Strong balance sheetStrong balance sheet — $3.3B cash & investments